D Orazio & Associates Inc. Has $490,000 Stock Holdings in McKesson Co. (NYSE:MCK)

D Orazio & Associates Inc. decreased its holdings in shares of McKesson Co. (NYSE:MCK) by 3.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 992 shares of the company’s stock after selling 33 shares during the quarter. D Orazio & Associates Inc.’s holdings in McKesson were worth $490,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in MCK. Headlands Technologies LLC acquired a new stake in McKesson during the 1st quarter valued at $67,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in McKesson by 5.6% during the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 125,380 shares of the company’s stock valued at $67,310,000 after purchasing an additional 6,636 shares during the last quarter. Koshinski Asset Management Inc. acquired a new stake in shares of McKesson during the first quarter worth $1,506,000. State Board of Administration of Florida Retirement System lifted its holdings in shares of McKesson by 10.4% during the first quarter. State Board of Administration of Florida Retirement System now owns 154,904 shares of the company’s stock worth $83,160,000 after buying an additional 14,625 shares in the last quarter. Finally, Angeles Wealth Management LLC acquired a new stake in shares of McKesson during the first quarter worth $220,000. Institutional investors and hedge funds own 85.07% of the company’s stock.

McKesson Trading Up 1.3 %

McKesson stock traded up $7.86 during midday trading on Wednesday, reaching $625.52. The company’s stock had a trading volume of 124,121 shares, compared to its average volume of 821,967. McKesson Co. has a 52 week low of $431.35 and a 52 week high of $637.51. The business has a 50-day moving average price of $515.00 and a 200-day moving average price of $552.91. The stock has a market cap of $79.40 billion, a PE ratio of 32.30, a price-to-earnings-growth ratio of 1.33 and a beta of 0.44.

McKesson (NYSE:MCK) last released its quarterly earnings results on Wednesday, November 6th. The company reported $7.07 earnings per share for the quarter, topping the consensus estimate of $6.88 by $0.19. The company had revenue of $93.65 billion for the quarter, compared to analysts’ expectations of $89.33 billion. McKesson had a negative return on equity of 207.50% and a net margin of 0.77%. The business’s quarterly revenue was up 21.3% compared to the same quarter last year. During the same period in the previous year, the business posted $6.23 earnings per share. As a group, research analysts predict that McKesson Co. will post 32.81 EPS for the current fiscal year.

McKesson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, January 2nd. Stockholders of record on Monday, December 2nd will be issued a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 0.45%. The ex-dividend date is Monday, December 2nd. McKesson’s dividend payout ratio (DPR) is currently 14.71%.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on MCK shares. Citigroup dropped their target price on McKesson from $670.00 to $630.00 and set a “buy” rating for the company in a report on Tuesday, September 10th. Wells Fargo & Company dropped their target price on McKesson from $576.00 to $535.00 and set an “equal weight” rating for the company in a report on Friday, September 13th. Barclays lifted their target price on McKesson from $596.00 to $616.00 and gave the stock an “overweight” rating in a report on Thursday, August 8th. StockNews.com raised McKesson from a “hold” rating to a “buy” rating in a report on Wednesday, November 6th. Finally, Robert W. Baird raised McKesson from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from $531.00 to $688.00 in a report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $625.64.

Insider Transactions at McKesson

In other news, CEO Brian S. Tyler sold 3,753 shares of the business’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $561.10, for a total transaction of $2,105,808.30. Following the sale, the chief executive officer now directly owns 78,586 shares in the company, valued at approximately $44,094,604.60. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.11% of the company’s stock.

McKesson Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.